5 companies

Mabylon AG

http://www.mabylon.com/  

8952 Schlieren, Wagistrasse 14

 +41 44 731 94 09
 info@mabylon.com

Mabylon is a biotechnology company spawned from the research of Prof. Adriano Aguzzi and his colleagues at the University of Zurich (UZH) and the University Hospital of Zurich (USZ). Mabylon is active in the field of human antibodies against prions, severe food allergies, and other intractable human diseases. Mabylon employs modern high-throughput technologies to screen for the presence of therapeutically relevant antibodies within large human populations. Up to 2'000 serum samples per day are screened using robots and miniaturized assays. Lymphocytes from seropositive carriers are then isolated, and their antibody genes are cloned.

Mabylon AG

Wagistrasse 14

8952 Schlieren

Memo Therapeutics AG

https://memo-therapeutics.com/  

8952 Schlieren, Wagistrasse 27


 info@memo-therapeutics.com

Memo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. Exploiting the power of our microfluidic single-cell molecular cloning and screening technologies we engage in antibody discovery across species and indications for proprietary and partnered projects. Our current pipeline features programmes in infectious diseases and immuno-oncology. MemoMAB discovery uses robust, simple and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency and sensitivity. MemoMAB captures and preserves entire B cell repertoires from any donor species and any B cell type in recombinant form and displays them in mammalian cells, maintaining the cognate heavy and light chain pairing of the original B cells throughout the process.

Memo Therapeutics AG

Wagistrasse 27

8952 Schlieren

Microcaps AG

https://www.microcaps.ch/  

8952 Schlieren, Wagistrasse 13

 +41 44 733 45 50
 alessandro.ofner@microcaps.ch

Making sure that drugs are released in the affected part of the body and at a specific rate is a huge challenge, because the size of the capsules that deliver these active ingredients is uncontrollable. At Microcaps we developed a patented technology that enables the size control of these microcapsules with Swiss precision, hence they all behave exactly the same. This means we can directly tailor and predict the release profile of a drug. Our solution is also highly relevant for fragrances, flavors and probiotics.

Microcaps AG

Wagistrasse 13

8952 Schlieren

MIDATA Genossenschaft

https://www.midata.coop/  

8005 Zürich, c/o EvalueScience AG – Pfingstweidstrasse 16


 info@midata.coop

MIDATA.coop enables citizens to securely store, manage and control access to their personal data by helping them to establish and own national/regional not-for-profit MIDATA cooperatives. MIDATA’s initial focus will be on health related data since these are most sensitive and valuable for one’s personal health. MIDATA cooperatives act as the fiduciaries of their members’ data. As MIDATA members, citizens can visualize and analyze their personal data. They can actively contribute to medical research and to clinical trials by providing access to sets of their personal data across cooperatives.

MIDATA Genossenschaft

c/o EvalueScience AG – Pfingstweidstrasse 16

8005 Zürich

Molecular Partners AG

http://www.molecularpartners.com  

8952 Schlieren, Wagistrasse 14

 +41 44 755 77 00

Molecular Partners AG is a clinical-stage biopharmaceutical company, located in Schlieren, Switzerland, that is developing a new class of therapies known as DARPin® therapies.

Molecular Partners AG

Wagistrasse 14

8952 Schlieren

Back to top